TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2115308
Drug: Metrifonate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (10 mg/kg, repeated at 4 month intervals)
Study: 18850387
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (postmenopausal women)
Study: 14535021
Drug: 654‐2 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 654‐2 injection and 'Gan Xian Tui Huang Recipe'
Study: 17116834
Drug: Imiquimod treatment
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod treatment
Study: 17038243
Drug: Standard nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nutrition support + Gln 100 ml/d + rhGH 10 U/d (Group C)
Study: 17038243
Drug: Standard nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nutrition support + 10% Gln 100 ml/d (Group B)
Study: 12812018
Drug: Transdermal Nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal Nicotine System (TNS) for 3 weeks
Study: 12812018
Drug: Transdermal Nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal Nicotine System (TNS) for 6 weeks
Study: 11157426
Drug: Control drugs
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drugs (tricyclics/heterocyclics and SSRIs)
Study: 3299016
Drug: MK-733 (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-733 (low dose: 2.5-10 mg/day)
Study: 3299016
Drug: MK-733 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-733 (high dose: 20-80 mg/day)
Study: 28624696
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of trastuzumab after chemotherapy
Study: 21705493
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of intravenous iron (III)-hydroxide sucrose
Study: 16957676
Drug: Estromineral serena
Normalized name: Serenoa preparation
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estromineral serena (ES) - 1 tablet/day for 24 weeks
Study: 15077843
Drug: Outpatient substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient substance abuse treatment
Study: 12573306
Drug: Climodien (estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Climodien (estradiol valerate 2 mg + dienogest 3 mg)
Study: 11304940
Drug: Climodien (estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Climodien (estradiol valerate 2 mg + dienogest 2 mg)
Study: 9034258
Drug: 4% albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% albumin solution (0.6 g/kg) administered after withdrawing 15 mL/kg of blood over 30 mins in group 2.
Study: 8509529
Drug: Alternative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative therapy after combination therapy was discontinued
Study: 30943512
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment of the primary tumour and lymph nodes metastasis
Study: 30943512
Drug: Non-surgical approaches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical approaches (including radiotherapy and systemic medical treatment)
Study: 29512061
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiotherapy
Study: 27019066
Drug: Citalopram infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram infusion
Study: 16996783
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis combined with pre and postsurgery hyperbaric oxygen (HBO) treatment
Study: 16199795
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER (75‐225 mg/day)
Study: 12022898
Drug: Regular coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular coffee (180 mg caffeine in 200 mL beverage)
Study: 12022898
Drug: Decaffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated coffee (3.6 mg caffeine in 200 mL beverage)
Study: 8521744
Drug: Teicoplanin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (400 mg once daily)
Study: 1968308
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg) after 17 h during dopamine infusion
Study: 26555945
Drug: Mammalian target
Normalized name: Mammalian target of rapamycin (mTOR) kinase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mammalian target of rapamycin inhibitor-free immunosuppression (group A)
Study: 17403819
Drug: Drainage, irrigation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drainage, irrigation, and fibrinolytic therapy
Study: 17403819
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (tapping of cerebrospinal fluid by reservoir)
Study: 9616309
Drug: Budesonide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (3 x 1 mg/day)
Study: 2558829
Drug: UFH regimen:
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH regimen: 5,000 IU bolus and 1,500 IU/h infusion
Study: 8348875
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (100 mg)
Study: 19236643
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg x kg(‐1) propofol
Study: 19526159
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg x kg(‐1) metoclopramide
Study: 18001178
Drug: No ablative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ablative therapy (n = 42)
Study: 16200556
Drug: Home chemotherapy
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home chemotherapy
Study: 12151468
Drug: Risperidone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.5 to 3.5 mg per day)
Study: 9849978
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (concomitant injections of M-M-R II, VARIVAX, and TETRAMUNE)
Study: 9849978
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (VARIVAX injection sites)
Study: 805050
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 mg, 3 times daily)
Study: 28617807
Drug: Methylprednisolone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 0.5 mg/kg/tpd with β-lactam plus macrolide
Study: 28617807
Drug: Methylprednisolone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 0.5 mg/kg/tpd with β-lactam plus fluoroquinolone
Study: 19713654
Drug: Bilateral stellate
Normalized name: Mastocarpus stellatus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral stellate ganglion block with 8 ml 1% lidocaine solution
Study: 17908769
Drug: IL6‐174 G/G
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL6‐174 G/G genotype
Study: 17908769
Drug: TNFA promoter
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TNFA promoter genotypes ‐238 G/G and ‐376 G/G, TLR4 299 A/A genotype
Study: 17908769
Drug: TNFA‐238 G/G
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFA‐238 G/G genotype or TNFA‐863 A allele carriage
Study: 7812483
Drug: Metal subcutaneous
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metal subcutaneous needle
Study: 7812483
Drug: Volume of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume of medication injected per day
Study: 340140
Drug: Aluminium hydroxide
Normalized name: Aluminium hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminium hydroxide B.P. tablets (500 mg)
Study: 31080025
Drug: Simple nasal
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple nasal external compression (saline solution)
Study: 17992378
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment + brief psychological intervention (LSPI)
Study: 17992378
Drug: Conventional pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pharmacological treatment (CT)
Study: 17992378
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment + guidance program (OG)
Study: 11028250
Drug: Rofecoxib 25
Normalized name: rofecoxib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 25 mg qd
Study: 10470596
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg tid
Study: 15338504
Drug: Ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 800 mg tid
Study: 11028250
Drug: Sodium naproxen
Normalized name: Naproxen Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium naproxen 550 mg bid
Study: 8746167
Drug: radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: radioiodine therapy (aRIT)
Study: 1326349
Drug: Rifabutin (B)
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin (B) daily
Study: 1326349
Drug: Rifampicin (R)
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin (R) daily
Study: 2185303
Drug: Milnacipran 100
Normalized name: milnacipran 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran 100 mg/d
Study: 22265923
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 50mg every day for 5 days (days 3-7 of cycle)
Study: 7657280
Drug: Ursodiol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodiol (10 to 12 mg/kg at bedtime for 2 years)
Study: 31654328
Drug: Upadacitinib extended-release
Normalized name: upadacitinib Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib extended-release formulations (four different formulations)
Study: 31654328
Drug: Upadacitinib immediate-release
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib immediate-release capsule formulation
Study: 31654328
Drug: External validation
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External validation formulation
Study: 25795697
Drug: Preferring medications
Normalized name: Proferrin
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preferring medications
Study: 23632142
Drug: Whole-home exercise
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-home exercise intervention (training for care home staff and twice-weekly physiotherapist-led exercise group)
Study: 21277231
Drug: Levetiracetam 1500
Normalized name: levetiracetam 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam 1500 mg daily divided in two doses for 12 weeks
Study: 8452171
Drug: Fleroxacin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin, 400 mg intravenously once a day
Study: 24040947
Drug: A100 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: A100 1.8 mL
Study: 24040947
Drug: A100 3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: A100 3.6 mL
Study: 1957404
Drug: Human serum
Normalized name: Human serum albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human serum albumin (hSA) 200 mg/ml
Study: 31594736
Drug: Single intravesical
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravesical instillation (SIC) with epirubicin 50 mg
Study: 31594736
Drug: Maintenance intravesical
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance intravesical chemotherapy (MIC) once weekly for 6 weeks plus once monthly for 1 year
Study: 27785737
Drug: Entospletinib (25-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entospletinib (25-1200 mg; fasted) as single or twice-daily oral doses for 7 days
Study: 27785737
Drug: Entospletinib (≥600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entospletinib (≥600 mg twice daily)
Study: 29806665
Drug: 6 mm
Normalized name: I-Port, 6 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mm long implants
Study: 21742400
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT), administered daily for a total of 20 treatments.
Study: 10430112
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg celecoxib twice a day
Study: 16772765
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg acetazolamide twice a day
Study: 11904978
Drug: rhuMAb‐E25 (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhuMAb‐E25 (recombinant humanized monoclonal anti‐IgE antibody)
Study: 9818888
Drug: Antimigraine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimigraine therapy
Study: 606784
Drug: Split-product vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-product vaccines
Study: 606784
Drug: Whole-virus vaccines
Normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-virus vaccines
Study: 26304663
Drug: CABG plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CABG plus medical therapy
Study: 7769367
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic hormone (ANH) at medium dose (1.8 pmol/kg/min)
Study: 30830974
Drug: MDT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDT treatment allocation agreement
Study: 30830974
Drug: MDT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDT treatment allocation agreement (Krippendorff's α)
Study: 30830974
Drug: MDT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDT treatment allocation where resectability assessments were concordant
Study: 29158678
Drug: DFN-15 120
Normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [DFNDR SUNSCREEN SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFN-15 120 mg
Study: 28748412
Drug: DFN-15 180
Normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [DFNDR SUNSCREEN SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFN-15 180 mg
Study: 29158678
Drug: DFN-15 240
Normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [DFNDR SUNSCREEN SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFN-15 240 mg
Study: 25971957
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 4 mg ondansetron
Study: 25971957
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 ml normal saline)
Study: 23417765
Drug: Blonanserin under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blonanserin under fasting (single dose 4, 8, and 12 mg)
Study: 23417765
Drug: Blonanserin under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blonanserin under food intake (single dose 8 mg)
Study: 21236333
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (500mg twice per day)
Study: 18783388
Drug: On-demand treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand treatment with esomeprazole 20 mg
Study: 18783388
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with esomeprazole 20 mg once a day
Study: 11713439
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (0.3 mg/kg/wk)
Study: 8422091
Drug: Growth hormone-releasing
Normalized name: Growth hormone-releasing peptide 2
DrugBank: Pralmorelin (DB18252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Growth hormone-releasing factor (GH-RF)
Study: 3630291
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase short-term lysis
Study: 3630291
Drug: Conventional heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional heparin phenprocoumon treatment
Study: 30753101
Drug: SynGEM (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: SynGEM (both doses)
Study: 8603242
Drug: Human corticotropin-releasing
Normalized name: Human corticotropin-releasing factor
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human corticotropin-releasing factor (hCRF) at doses of 2, 4, and 8 mu g/kg body weight
Study: 8603242
Drug: Human corticotropin-releasing
Normalized name: Human corticotropin-releasing factor
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human corticotropin-releasing factor (hCRF) at 8 mu g/kg
Study: 30076800
Drug: REMOTE-CR (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: REMOTE-CR (12 weeks of individualized exercise prescription, real-time physiological monitoring, coaching, and behavioral support)
Study: 19357525
Drug: L-acetylcarnitine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-acetylcarnitine + BCAA
Study: 16872787
Drug: Tailored intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tailored intervention with booster dose
Study: 16872787
Drug: Tailored intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tailored intervention without booster dose
Study: 15159241
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (4.5 g/d during the first 4 months of lactation)
Study: 15159241
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein intake (measured as g/d)
Study: 16552194
Drug: Intergel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intergel treatment (0.5% ferric hyaluronate gel)
Study: 16552194
Drug: Intergel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intergel treatment
Study: 29655061
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy alone
Study: 3550556
Drug: Concomitant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemotherapy and endocrine therapy
Study: 27613076
Drug: DFN-02 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFN-02 (10 mg sumatriptan plus 0.20% DDM)
Study: 1333181
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg subcutaneous sumatriptan
Study: 17221340
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg subcutaneous sumatriptan
Study: 15663589
Drug: 2.5 mg/day
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/day oral tibolone
Study: 2265045
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg kg‐1
Study: 2787664
Drug: Thiopentone 5
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 5 mg kg‐1
Study: 3519225
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose furosemide (120 mg i.v. during the initial 24 hours)
Study: 3519225
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose furosemide (20 mg i.v. during the initial 24 hours)
Study: 27130973
Drug: Conventional anti-VEGF
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Conventional anti-VEGF therapy
Study: 24351072
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of myo-inositol/die plus 400 mcg of folic acid/die orally for six months
Study: 19523875
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (1000 mg/day for 12 weeks)
Study: 15831642
Drug: Cardiac Resynchronisation
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronisation Therapy (CRT)
Study: 14568269
Drug: 9 mcg
Normalized name: Nasarel, 29 mcg/inh nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mcg of consensus interferon plus ribavirin (1000/1200 mg/daily) for 24 weeks (group A)
Study: 14568269
Drug: 18 mcg
Normalized name: Spiriva, 18 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mcg of consensus interferon plus ribavirin (1000/1200 mg/daily) for 24 weeks (group B)
Study: 14568269
Drug: 9 mcg
Normalized name: Nasarel, 29 mcg/inh nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mcg of consensus interferon plus ribavirin for 48 weeks (group C)
Study: 14568269
Drug: 18 mcg
Normalized name: Spiriva, 18 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mcg of consensus interferon plus ribavirin for 48 weeks (group D)
Study: 14568269
Drug: 9 mcg
Normalized name: Nasarel, 29 mcg/inh nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mcg of consensus interferon plus ribavirin for 48 weeks in naive genotype 1 patients
Study: 8982555
Drug: 1α-hydroxycalciferol (1α[OH]D3)
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1α-hydroxycalciferol (1α[OH]D3) at a low dose (0.25 μg/day, n = 56, Group L)
Study: 8982555
Drug: 1α-hydroxycalciferol (1α[OH]D3)
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1α-hydroxycalciferol (1α[OH]D3) at a higher dose (0.5 to 1.0 μg/day, average 0.58 ± 0.02 μg/day, n = 65, Group H)
Study: 8982555
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n = 44, Group N)